Latest News
Jones Act Waiver Extended 90 Days with Stricter Per-Voyage Scrutiny
President Trump extends Jones Act waiver for 90 days, but new approvals require case-by-case review. Oil jumps 5% as Hormuz uncertainty persists.
Silence Therapeutics Soars on Quarterly Dosing Data for Divesiran
Silence Therapeutics (SLN) surged 25%+ as Phase 2 data validated 12-week dosing for divesiran in polycythemia vera, with 88% response rate versus 19% placebo.
Sandisk Shares Climb as Analysts Reassess Post-Earnings Drop
Sandisk shares rose 1.9% on Monday as analysts reframed last week's earnings selloff, with Argus upgrading to Buy and a $1,600 target.
CEVA Stock Plunges 16% as Royalty Growth Trails AI Licensing Boom
CEVA shares tumbled 16% after Q2 results showed a licensing surge but royalty growth of only 1%, as AI design wins have yet to generate production revenue.
Tesla Stock Stalls Despite Retail Buying Surge as Valuation Hits 300x Earnings
Tesla shares remained nearly unchanged despite a tripling of retail purchases to $372 million, as valuation concerns persist with the stock trading at over 300 times earnings.
S&P 500 Options Sentiment Hits 4-Year Bullish Peak as Rally Loses Steam
S&P 500 call-to-put ratio hits 0.9, a four-year high, even as index slips. JPMorgan raises target to 8,000, but limited upside remains.
Meta Stock Slips as Muse Hype Meets $145B Spending Reality
Meta shares faded after the Muse Glimmer launch, with investors questioning whether AI offerings justify the company's massive $145B capital spending plan.
Lilly's Foundayo Wins UK Approval, Lifting Shares Nearly 3%
Eli Lilly's (LLY) shares jumped 2.9% after the UK became the first European country to approve its oral weight-loss drug Foundayo, adding about $30 billion to its market value.
Strategy Boosts Cash Reserves to $4.65B via $653M Stock Sale, Trims Bitcoin
Strategy raised $653M via stock sales, boosting cash reserves to $4.65B, while selling 1,690 BTC to fund preferred share buybacks. MSTR fell 3%.